相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1890
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- ASCO's 2025 guidelines recommend a more selective approach to surgery for pleural mesothelioma, limiting surgical intervention to early-stage epithelioid cases at specialized centers. - The guidelines establish immunotherapy combination ipilimumab/nivolumab as first-line treatment for non-epithelioid mesothelioma, based on significant survival benefits shown in the CheckMate 743 trial. - New recommendations include mandatory genetic testing for all mesothelioma patients, simplified disease terminology, and personalized treatment approaches incorporating immunotherapy, chemotherapy, or combination regimens.
• Leading gastroenterologist Dr. David Rubin will provide expert insights on the ulcerative colitis treatment landscape and discuss Abivax's ABTECT Phase 3 trial of obefazimod. • The virtual event, scheduled for March 17, 2025, will explore obefazimod's potential to address unmet medical needs in ulcerative colitis treatment. • Attendees will have the opportunity to engage with Dr. Rubin and Abivax's management team during a live Q&A session following the presentation.
